#Active Pharmaceutical Ingredient market Size

[health-views-updates]

Active Pharmaceutical Ingredient Market: Future Opportunities and Challenges

Active Pharmaceutical Ingredient Market Outlook, Scope & Overview:

Industry reports indicate that the global active pharmaceutical ingredient (API) market was valued at USD 239.45 billion in 2023 and is projected to reach USD 371.06 billion by 2032, growing at a CAGR of 5.37% over the forecast period 2024-2032.

Technological Advancements to Drive Growth of Global Active Pharmaceutical Ingredient Market

The adoption of advanced manufacturing technologies and increasing investments in research and development will continue to influence global market revenues. Pharmaceutical companies are increasingly focusing on the development and production of high-quality APIs to meet the rising demand for effective and safe medications.

As a product segment, synthetic APIs currently hold a significant share of the global API market. This segment is anticipated to grow at a year-over-year rate of 5.37% in 2024 over 2023 and reach USD 371.06 billion in revenues by 2032. The increasing prevalence of chronic diseases, coupled with the growing need for innovative therapeutic drugs, is expected to drive market growth.

Active Pharmaceutical Ingredient Solutions – Market Dynamics

Drivers:

The API market is witnessing significant growth in the global market due to the rising demand for generic and branded drugs, the increasing prevalence of chronic diseases, and the growing emphasis on personalized medicine. Technological advancements in API manufacturing, such as the adoption of continuous manufacturing processes and green chemistry, are also key factors driving the adoption of APIs worldwide. Additionally, favorable government regulations and policies supporting pharmaceutical manufacturing are further propelling market growth.

Restraints:

Despite the growth potential, challenges such as stringent regulatory requirements, high manufacturing costs, and the complexity of API production processes are hindering the widespread adoption of APIs. Moreover, the need for substantial investments in research and development, as well as the potential for supply chain disruptions, pose additional challenges to market expansion.

Active Pharmaceutical Ingredient Solutions – Market Outlook

The proven benefits of APIs in drug development, efficacy, and safety have contributed to the market's growth. APIs are expected to witness increased adoption across major pharmaceutical markets, including North America, Europe, and Asia Pacific, driven by advancements in manufacturing technologies and the growing demand for innovative and cost-effective medications.

Global Active Pharmaceutical Ingredient Market

The rise in demand for APIs in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global API market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of APIs, supported by favorable regulatory frameworks and increasing investments in pharmaceutical research and development.

Key Players in the Active Pharmaceutical Ingredient Solutions Market

Leading companies in the active pharmaceutical ingredient solutions market include Pfizer, Inc., Novartis International AG, Sanofi, and Teva Pharmaceutical Industries Ltd. These companies are at the forefront of developing and commercializing advanced API technologies for various therapeutic applications, including oncology, cardiovascular diseases, and infectious diseases.

In conclusion, the global active pharmaceutical ingredient market is poised for substantial growth over the forecast period, driven by technological advancements, increasing demand for effective medications, and the expanding adoption of innovative manufacturing processes across diverse pharmaceutical settings.

Other Trending Reports

AI in Pathology Market Share by Company

Healthcare Education Market Share by Company

Wearable Medical Devices Market Share by Company

Medical Foam Market Share by Company

[alicetleibowitz]

The Active Pharmaceutical Ingredient (API) market is experiencing significant growth driven by increased demand for pharmaceuticals, advancements in API manufacturing, and rising prevalence of chronic diseases, shaping a robust and dynamic market landscape.

[bishtmeenakshi]

Unveiling the Dynamics of the Active Pharmaceutical Ingredient Market

Delve into the intricate dynamics of the Active Pharmaceutical Ingredient market, analyzing its size, segmentation, revenue, growth rate, trends, and forecasts. Gain valuable insights from comprehensive API market analysis reports.

[marketsndata]

[luckydige45]

According to latest report, the global active pharmaceutical ingredient CDMO market size was estimated at USD 119.80 billion in 2023 and is projected to hit around USD 249.22 billion by 2033, growing at a CAGR of 7.6% during the forecast period from 2024 to 2033. Asia Pacific had dominated in the market with the largest revenue share of 38.11% in 2023.

[industrynewsupdates]

Active Pharmaceutical Ingredients Market: Key Companies and Emerging Trends 2024-2030

The global active pharmaceutical ingredients market size was estimated at USD 237.47 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.75% from 2024 to 2030. 

Advancements in Active Pharmaceutical Ingredient (API) manufacturing, growth of the biopharmaceutical sector, and an increase in geriatric population are among the key drivers of API market. An increase in prevalence of chronic diseases, such as cardiovascular diseases and cancer, is anticipated to boost market growth.

Global geriatric population is increasing. According to UN, in 2022, people aged 65 and above accounted for 771 million of the population, and the number is anticipated to reach 994 million by 2030 to 1.6 billion by 2050. The number of elderly people is showing fastest growth in Africa, with a threefold increase estimated in people aged 60 and above, followed by Latin America, reaching 18.8 billion by 2050. Aging is considered the greatest risk factor for development of diseases, including cardiovascular and neurological diseases. Thus, rapidly growing global geriatric population is resulting to be a high-impact-rendering driver for API market.

Gather more insights about the market drivers, restrains and growth of the Active Pharmaceutical Ingredients Market

Increasing prevalence of infectious diseases and hospital-acquired infections is driving market growth. In addition, growing incidence of cardiovascular, genetic, and neurologic disorders is anticipated to act as a high-impact-rendering driver for market growth. Cardiovascular Diseases (CVDs) are the most prevalent causes of death globally. According to WHO, cardiovascular diseases cause death of 17.9 million people per day and are expected to cause approximately 25 million deaths by 2030. Increasing epidemiology of lifestyle, aided with rising number of smokers globally, growing incidence of obesity, and increasing dietary irregularities, are factors likely responsible to propel market growth. A recent report by the United Nations (UN) in May 2023 suggests that there has been a 75% increase in the number of girls and 61% in the number of boys with obesity in Europe.

Outsourcing of APIs has become profitable over in-house production. However, this trend took a different turn during the COVID-19 pandemic. Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer. In addition, risk mitigation is done using dual sourcing to ensure a continuous supply. Hence, key companies aim to capitalize on this ongoing outsourcing trend with new acquisitions. For instance, in August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry. This further demonstrates the company’s plans for vertical integration.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global antipsychotic drugs market size was valued at USD 16.88 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030. 

• The global drug and gene delivery devices market size was valued at USD 670.0 million in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.

Active Pharmaceutical Ingredients Market Report Segmentation

Grand View Research has segmented the global active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, type of drug, and region:

Type of Synthesis Outlook (Revenue, USD Billion, 2018 - 2030)

• Biotech

o Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)

o Generic APIs

o Innovative APIs

o Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)

o Monoclonal Antibodies

o Hormones

o Cytokines

o Recombinant Proteins

o Therapeutic Enzymes

o Vaccines

o Blood Factors

• Synthetic

o Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)

o Generic APIs

o Innovative APIs

Type of Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)

• Captive APIs

• Merchant APIs

Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Generic APIs

• Innovative APIs

Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Cardiovascular Diseases

• Oncology

• CNS and Neurology

• Orthopedic

• Endocrinology

• Pulmonology

• Gastroenterology

• Nephrology

• Ophthalmology

• Others

Key Companies & Market Share Insights

Some of the leading players operating in the active pharmaceutical ingredients market include AbbVie, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., and Eli Lilly and Company. Key players are using existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This marketing strategy is useful for brands that have already built trust in the market. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process & analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.

Evonik, CARBOGEN AMCIS, and Pharmazell, are some of the emerging market participants in the ophthalmic drugs market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues. 

Key Active Pharmaceutical Ingredients Companies:

• Dr. Reddy’s Laboratories Ltd.

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceutical Industries Ltd.

• Cipla Inc.

• AbbVie Inc.

• Aurobindo Pharma

• Sandoz International GmbH (Novartis AG)

• Viatris Inc.

• Fresenius Kabi AG

• STADA Arzneimittel AG

Recent Developments

• In August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry.

• In July 2023, Teva Pharmaceutical Industries Ltd. designed a new strategy for development with potential sale of its API unit on the table. The API manufacturing facility is worth USD 2 billion.

• In June 2023, Lonza acquired Synaffix to improve its ADC services portfolio.

• In April 2023, Eli Lilly announced an investment of USD 1.6 billion in the U.S.-based LEAP Innovation Park. This brings the total investment to USD 3.7 billion to manufacture complex APIs for products such as genetic medicine.

• In February 2023, Lonza completed the manufacturing of its facility in Switzerland. The company enhanced its capacity for its High Potent Active Pharmaceutical Ingredient (HPAPI) manufacturing facility.

• In January 2023, Sterling Pharma Solutions acquired an API manufacturing facility from Novartis in Ringaskiddy, Ireland.

Order a free sample PDF of the Active Pharmaceutical Ingredients Market Intelligence Study, published by Grand View Research. 

[mitalipingale]

https://twikkers.nl/blogs/250818/Veterinary-Active-Pharmaceutical-Ingredients-Manufacturing-Market-Share-Overview-Competitive-Analysis

The Veterinary Active Pharmaceutical Ingredients Manufacturing Market in 2023 is US$ 6.73 billion, and is expected to reach US$ 11.66 billion by 2031 at a CAGR of 7.10%.

[renubresearch]

Active Pharmaceutical Ingredients Market will be US$ 377.05 Billion by 2032

Active Pharmaceutical Ingredients Market Analysis Active Pharmaceutical Ingredients Market is projected to reach US$ 212.12 billion in 2023 and is expected to reach US$ 377.05 billion by 2032, growing at a CAGR of % from 2024 to 2032. The active pharmaceutical ingredient (API) is the key biologically active component in pharmaceutical products, responsible for their therapeutic effects. APIs…

[soumyafwr]

https://uchatoo.com/read-blog/4705_specialty-active-pharmaceutical-ingredients-market-size-analysis-and-forecast-20.html

Specialty Active Pharmaceutical Ingredients Market Size, Analysis and Forecast 2031

[marketreports-blog]

The global high potency active pharmaceutical ingredients market size was exhibited at USD 26.18 billion in 2023 and is projected to hit around USD 50.55 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2024 to 2033.

[blog-site-for-market-research]

Active Pharmaceutical Ingredients Market Research, Opportunity Analysis and Industry Forecast, 2023-2032

The burgeoning number of illnesses requiring medicines are estimated to bolster the active pharmaceutical ingredient market in the future. The Active Pharmaceutical Ingredients Market Size was assessed at USD 277.1 billion in 2021 and is expected to increase from USD 299.21 billion in 2022 to USD 512.13 billion by 2030, with a compound annual growth rate (CAGR) of 7.98% within the forecast period (2022– 2030).

The escalation in the use of combined drug therapies is estimated to promote the overall active pharmaceutical ingredient market companies’ progress in the approaching period. Moreover, the demand for generic drugs is predicted to further create lucrative growth opportunities in the active pharmaceutical ingredient market.

Segmental Analysis

The segmental scrutiny of the active pharmaceutical ingredient market is conducted on the basis of application, manufacturing process, type of synthesis, API formulation, molecule, and region. The manufacturing process based segmentation of the active pharmaceutical ingredient market comprises of captive manufacturing and contract manufacturing. The type of synthesis segment of the active pharmaceutical ingredient market consists of the synthetic segment and the biotech segment.  The API formulation of the active pharmaceutical ingredient market comprises of generic API and innovative API. The application-based segmentation of the active pharmaceutical ingredient market includes oncology, neurological disorders, respiratory, urology, gastrointestinal disorders, cardiovascular disease, orthopedic disorders, and others. The molecule-based segmentation of the active pharmaceutical ingredient market comprises of small molecules and large molecules.

Detailed Regional Analysis 

The regional assessment of the active pharmaceutical ingredient market consists of the Americas, Europe, Asia Pacific, and other regions. The Americas regional active pharmaceutical ingredients market research is projected to hold the primary share of the global market. The North American region leads in the Americas region due to the growing technological advancement in diagnostics connected with the mounting incidences of prolonged diseases and other neurological states. The active pharmaceutical ingredient market in Europe is anticipated to report for the subsequent market portion throughout the forecast period. Many CMOs existing in producing APIs and the escalating need to progress generic drugs are assumed to spur the regional market. The Asia Pacific region’s active pharmaceutical ingredient market is gauged to be the fastest developing region in the global market due to the prevalence of rapidly emerging diseases in the region.

Competitive Analysis

The improvement in core industries performance on a global scale is estimated to fast track the development of the worldwide market in the upcoming period. The overall development prospects of the market players are estimated to improve steadily with the effect of the COVID-19 pandemic reducing. The entry of global players in key developing regional markets is predicted to have a favorable effect that will ripple into other areas of the market as well. The role of governmental bodies in facilitating the development of the market is estimated to be vital through the grant of special incentives to attract global titans to certain regions and contribute to the development of the market in the forecast period. Furthermore, the presence of better trade relations between several nations is estimated to offer more options for growth in the upcoming period. The optimism about COVID-19 related treatment methods such as the vaccines being rolled out in various regions is estimated to further improve the overall sentiment in the market.

The promising companies in the active pharmaceutical ingredient market are Pfizer Inc., F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Bayer AG, GlaxoSmithKline Plc (GSK), Sanofi, Eli Lilly and Company, Abbott Laboratories, Novartis AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[informationandcommunication]

The manufacturers are involved in developing advanced drugs for different diseases. Investments in research and developments to enhance the capabilities of high-performance active pharmaceutical ingredients (HPAPI) are supporting the market growth.

[bishtmeenakshi]

Insights into Trends in the Evolving Pharmaceutical Landscape

Discover trends shaping the evolving pharmaceutical landscape. Explore market size, revenue, growth rate, and insights from the Active Pharmaceutical Ingredient Market Report for a comprehensive view of the dynamic industry.

[marketsndata]

[luckydige45]

As per the report from nova one advisor, the global Active Pharmaceutical Ingredients market size was exhibited at USD 236.07 billion in 2023 and is projected to hit around USD 395.8 billion by 2032, growing at a CAGR of 5.91% during the forecast period 2023 to 2032.

[brostateexam]

It turns out she’s down about ten pounds and happy about it. “Somebody once told me I had a size-zero personality, and they assumed that I was thinner than I was,” she tells me. “We don’t talk about it, but everybody knows it. Thin is power.”

Allison isn’t alone in seeming to be suddenly, unaccountably slimmer of late. She admitted to me — with the provision that I not use her real name — the reason, one that is increasingly common if still not quite openly discussed. For the past month, she’s been jabbing herself every week with Ozempic, the heavily advertised (“Oh, oh, oh, Ozempic,” to the tune, none too subtly, of the ’70s classic-rock hit “Magic”) diabetes miracle drug, which works by mimicking a naturally occurring hormone, GLP-1 (glucagon-like peptide one), to manage hunger and slow stomach emptying.

For diabetics, it lowers blood-sugar levels. It also subdues the imp of appetite. The pounds fly off. That’s why Allison, who is not diabetic, prediabetic, or even overweight, is on it. Doctors have wide latitude to prescribe drugs off label for anyone they think may medically benefit, and many patients have found doctors — or, failing that, nurse practitioners or medi-spas — ready to certify that they would. Or some, like Allison, find it through a peddler not particular about a prescription or in the web’s dark morass.

To get hers, Allison calls up a Los Angeles–based provider she has never seen or met, sends over $625, and is shipped a monthly supply. What she calls Ozempic is not the brand-name product pre-packaged in a sky-blue injector pen by Novo Nordisk, the Danish pharmaceutical company that makes and markets the drug. She receives generic semaglutide, the active ingredient in the medication, and has to mix and prepare it for injection herself, which — since semaglutide is under patent by Novo Nordisk until 2032 in the U.S. — suggests her meds are likely coming from a compounding pharmacy or a vendor selling research-grade ingredients. The lower price is also a tell: Ozempic retails for about $900 a month if your insurance doesn’t cover it.